• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.

    5/12/25 10:36:17 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    METSERA INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    59267L107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    15,167,808.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    15,167,808.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,167,808.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    15,167,808.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,167,808.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    METSERA INC
    (b)Address of issuer's principal executive offices:

    3 WORLD TRADE CENTER,175 GREENWICH STREET,New York,NY,USA,10007
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    59267L107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    15167808.00
    (b)Percent of class:

    14.4  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    15167808.00

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of METSERA INC. No one other person's interest in the COMMON STOCK of METSERA INC is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:05/09/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:05/09/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $MTSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.

      SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)

      5/12/25 10:36:17 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Metsera Inc.

      10-Q - Metsera, Inc. (0002040807) (Filer)

      5/12/25 7:30:23 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Metsera, Inc. (0002040807) (Filer)

      5/12/25 7:30:14 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Metsera with a new price target

      Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00

      2/25/25 7:57:00 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Metsera with a new price target

      BofA Securities initiated coverage of Metsera with a rating of Buy and set a new price target of $38.00

      2/25/25 7:56:39 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Metsera

      Evercore ISI initiated coverage of Metsera with a rating of Outperform

      2/25/25 7:56:13 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Pinto Joshua

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:42:42 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Chairman Meanwell Clive

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:40:27 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Burow Kristina

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:39:32 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:15:35 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:04:05 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:01:33 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

      MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025MET-097o, an oral formulation of MET-097i, has been accelerated and alternate oral candidate MET-224o is on track, with four-week data for selected lead expected in late 2025 $588 million cash and cash equivalents support runway into 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical compa

      5/12/25 7:00:11 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera to Present at Bank of America 2025 Global Healthcare Conference

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Bank of America 2025 Global Healthcare Conference on Wednesday, May 14 at 2:20 - 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT). A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines

      5/8/25 4:01:51 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

      MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1 Oral formulation optimization study on track to support initiation of clinical trials for MET-224o and MET097o, with MET-224o data expected in late 2025 Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027 NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medici

      3/26/25 7:00:37 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care